|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Brendan Kennedy||Chairman, Pres & CEO||850k||N/D||1972|
|Mr. Mark Castaneda||CFO & Treasurer||506k||N/D||1965|
|Mr. Edward Wood Pastorius Jr.||Chief Revenue Officer||433,2k||N/D||1968|
|Mr. Greg Christopher||Exec. VP of Operations||N/D||N/D||N/D|
|Ms. Dara Redler||Legal Gen. Counsel & Corp. Sec.||N/D||N/D||N/D|
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, and compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, the United Kingdom, the United States, and South Africa. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.
L'ISS Governance QualityScore di Tilray, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.